Market research
CARA Cara Therapeutic
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- Not available
- Beta
- 0.41
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US1407551092
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- Not available
- Beta
- 0.41
About
About Cara Therapeutic
Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CARA discussion.
5 years, 4 months ago
Cara Therapeutics, Inc is currently in a long term downtrend where the price is trading 18.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.4.
Cara Therapeutics, Inc's total revenue rose by 2384.8% to $112M since the same quarter in the previous year.
Its net income has increased by 375.8% to $79M since the same quarter in the previous year.
Finally, its free cash flow grew by 362.7% to $82M since the same quarter in the previous year.
Based on the above factors, Cara Therapeutics, Inc gets an overall score of 4/5.